# 💊 Drug-Induced Nephrotoxicity

**📘 Updated to reflect KDIGO 2026 draft Clinical Practice Guideline for AKI and AKD**

### 📋 Executive Summary

Drug-induced nephrotoxicity represents one of the most common causes of acute kidney injury in clinical practice, accounting for 15-25% of all AKI cases. Understanding the unique characteristics of medication-induced kidney injury is essential for early detection, appropriate prevention, and optimal management.

## 🔬 KDIGO 2026 draft Drug Classification Framework

Classifying drugs by kidney function markers and damage biomarkers (Figure 11)

[TABLE]

**This framework from KDIGO 2026 draft (Figure 11)** classifies drugs by whether they affect kidney function markers (SCr, GFR) and/or damage biomarkers (NGAL, KIM-1, TIMP-2×IGFBP7). This distinction is clinically critical:

- **Trimethoprim** raises creatinine by blocking tubular secretion — NOT real injury (no damage marker elevation)
- **ACEi/ARB** reduce GFR hemodynamically — dysfunction without damage (appropriate in many patients)
- **Aminoglycosides** cause tubular damage detectable by biomarkers BEFORE creatinine rises — damage without dysfunction initially
- **NSAIDs** cause both hemodynamic GFR reduction AND structural damage

## 🏥 Nephrotoxin Stewardship

KDIGO 2026 draft Rec 4.2.1 (1C) Multimodal drug and nephrotoxin stewardship recommended

#### 💊 Drug Management Strategies

- **(a)** Discontinue offending agent
- **(b)** Substitute less nephrotoxic alternative
- **(c)** Dose-reduce for dose-dependent effects

#### 🖥️ Clinical Decision Support

- CDSS endorsed as effective tools (PP 4.3.2)
- Electronic alerts for nephrotoxin exposure
- Automated dose adjustment recommendations

#### 👩‍⚕️ Pharmacist-Led Reconciliation

- Medication reconciliation for hospitalized patients with or at risk of AKI
- Surveillance for pharmacokinetic/pharmacodynamic drug-drug interactions (PP 4.2.3)

#### 🛡️ Prevention Measures

- IV hydration for prevention of drug-induced crystalline nephropathies (PP 4.2.4)
- Therapeutic drug monitoring for narrow-margin drugs (vancomycin, aminoglycosides, calcineurin inhibitors)

## 💊 Drug Classes by Nephrotoxicity Risk & Mechanism

Overview of major drug classes with their mechanisms, onset timing, and injury patterns

| Drug Class | Primary Mechanism | Typical Onset (Days) | Pattern of Injury | Incidence Rate | Prevention Strategy |
|----|----|----|----|----|----|
| **Aminoglycosides** | Direct tubular toxicity | 7-10 | Acute tubular necrosis | 10-25% | Extended-interval dosing |
| **Glycopeptides (Vancomycin)** | Oxidative stress, inflammasome activation | 5-10 | Acute tubular necrosis | 5-35% | AUC-guided dosing |
| **Beta-Lactams** | Hypersensitivity reaction | 10-14 | Acute interstitial nephritis | 1-3% | Early recognition of AIN |
| **Polymyxins** | Membrane damage | 5-7 | Acute tubular necrosis | 20-60% | Optimal dosing strategies |
| **Fluoroquinolones** | Hypersensitivity reaction | 7-14 | Acute interstitial nephritis | \<1% | Dose adjustment in CKD |
| **Sulfonamides (Crystalluria)** | Crystal formation | 1-3 | Crystal nephropathy | 1-5% | Adequate hydration, alkalinization |
| **Tetracyclines** | Direct tubular toxicity | 3-7 | Fanconi syndrome | \<1% (modern agents) | Avoid expired formulations |
| **Macrolides** | Hypersensitivity, drug interactions | 7-14 | Acute interstitial nephritis | \<1% | Monitor drug interactions |
| **Amphotericin B** | Membrane damage | 5-7 | Acute tubular necrosis | 30-80% | Lipid formulations, hydration |
| **NSAIDs** | Prostaglandin inhibition | Variable | Hemodynamic AKI, AIN | Variable by risk factors | Avoid in high-risk patients |
| **PPIs** | Immune-mediated hypersensitivity | Days to months | Acute interstitial nephritis | Variable | Appropriate indication, duration |

### 🧬 Aminoglycosides: Structure-Toxicity Relationship

**Key Discovery:** Nephrotoxicity directly correlates with positive charge and number of amino groups

| Aminoglycoside | Relative Nephrotoxicity | Number of Amino Groups | Positive Charges | Clinical Notes |
|----|----|----|----|----|
| **Neomycin** | Highest (5/5) | 6 | +6 | Topical use only due to toxicity |
| **Gentamicin** | High (4/5) | 5 | +5 | Most commonly used, high efficacy |
| **Tobramycin** | Moderate to High (3/5) | 5 | +5 | Preferred for Pseudomonas |
| **Kanamycin** | Moderate (3/5) | 4 | +4 | Limited use due to resistance |
| **Amikacin** | Moderate (2/5) | 4 | +4 | Reserved for resistant organisms |
| **Netilmicin** | Low to Moderate (2/5) | 3 | +3 | Less nephrotoxic alternative |
| **Streptomycin** | Lowest (1/5) | 2 | +2 | Primarily ototoxic, less nephrotoxic |

#### 🔬 Mechanism of Charge-Related Toxicity

**1. Enhanced Membrane Binding**

Higher positive charge → stronger binding to negatively charged phospholipids in proximal tubular cells

**2. Increased Cellular Uptake**

More charges → greater megalin-mediated endocytosis → higher intracellular accumulation

**3. Enhanced Lysosomal Retention**

Highly charged molecules accumulate more in lysosomes → greater disruption of cellular function

**4. Mitochondrial Interference**

Greater positive charge → stronger binding to mitochondrial ribosomes → more energy disruption

### ⚠️ High-Risk Nephrotoxic Drug Combinations

Synergistic nephrotoxicity from commonly used drug combinations

#### 🔥 Vancomycin + Piperacillin-Tazobactam

**AKI Risk:** 21-40% (vs 8-13% vancomycin alone)\
**NNH:** 8-10 patients **Mechanism:** Synergistic NLRP3 inflammasome activation\
**Timeline:** Risk highest in first 7 days **Prevention:** AUC-guided vancomycin + extended-infusion pip-tazo\
**Alternative:** Vancomycin + cefepime or meropenem

#### ⚡ Vancomycin + Aminoglycosides

**AKI Risk:** 25-40% (historic high-risk combination)\
**Risk Factors:** Higher doses, extended duration **Mechanism:** Complementary nephrotoxic pathways\
**Enhanced uptake:** Vancomycin increases aminoglycoside tubular uptake **Management:** Avoid combination when possible\
**Monitoring:** Daily creatinine, enhanced surveillance

#### 💀 Polymyxins + Vancomycin

**AKI Risk:** 40-60% (extremely high-risk)\
**Indication:** Extensively drug-resistant organisms only **Mechanism:** Synergistic membrane damage + oxidative stress\
**Additive effects:** Multiple cellular injury pathways **Management:** Daily monitoring, nephroprotective strategies\
**Consider:** Newer agents when available

#### 🚨 "Triple Whammy" Effect

**Definition:** ACE-I/ARB + Diuretic + NSAID\
**Mechanism:** Disrupts all three major renal autoregulation mechanisms\
**Risk:** Rate ratio 1.31 overall, 1.82 in first 30 days\
**Fatality rate:** ~10% when AKI develops

## 🔬 Mechanisms of Drug-Induced Nephrotoxicity

### 🔥 Acute Tubular Necrosis (ATN)

**Drugs:** Aminoglycosides, Vancomycin, Polymyxins, Amphotericin B, Cisplatin **Mechanism:** Direct cellular toxicity, oxidative stress, membrane damage **Timeline:** 5-10 days (varies by drug) **Microscopy:** Muddy brown granular casts, tubular epithelial cells

### 🔵 Acute Interstitial Nephritis (AIN)

**Drugs:** PPIs, Beta-lactams, NSAIDs, Fluoroquinolones, Sulfonamides **Mechanism:** T-cell mediated hypersensitivity, immune complex formation **Timeline:** 7-14 days (typically delayed) **Microscopy:** WBC casts, eosinophils, sterile pyuria

### 💎 Crystal Nephropathy

**Drugs:** Sulfonamides, Acyclovir, Methotrexate, Uric acid (tumor lysis) **Mechanism:** Intratubular precipitation, obstruction **Timeline:** Hours to days **Microscopy:** Characteristic crystals, variable cellular response

## 🛡️ Evidence-Based Prevention Strategies

### 🔍 Risk Assessment

- Baseline kidney function assessment
- Identify high-risk patients
- Review concurrent medications
- Assess volume status
- Consider alternative agents

### 💊 Optimized Dosing

- **Vancomycin:** AUC-guided dosing (33-45% ↓ risk)
- **Aminoglycosides:** Extended-interval dosing (30-50% ↓ risk)
- **All drugs:** Lowest effective dose, shortest duration
- Adjust for kidney function
- Therapeutic drug monitoring when available

### 🔬 Enhanced Monitoring

- Daily creatinine in high-risk patients
- Early biomarker detection (NGAL, KIM-1)
- Drug level monitoring
- Electrolyte surveillance
- Urine output tracking

### 💧 Supportive Care

- Maintain adequate hydration
- Avoid concurrent nephrotoxins
- Optimize hemodynamics
- Correct electrolyte abnormalities
- Consider nephroprotective strategies

## ⏰ Temporal Patterns of Drug-Induced Nephrotoxicity

Understanding onset timing is crucial for early recognition and intervention

1-3

#### Immediate Onset (Hours to 3 Days)

**Drugs:** Sulfonamide crystalluria, contrast agents, hemodynamic drugs (NSAIDs in volume-depleted patients)

**Mechanism:** Crystal formation, acute hemodynamic changes, direct tubular toxicity

**Clinical Action:** Immediate drug discontinuation, aggressive hydration, alkalinization for crystals

5-7

#### Early Onset (5-7 Days)

**Drugs:** Polymyxins, Amphotericin B, Vancomycin

**Mechanism:** Direct membrane damage, oxidative stress, early inflammatory responses

**Clinical Action:** Dose adjustment, enhance monitoring, consider alternative formulations

7-10

#### Classic Onset (7-10 Days)

**Drugs:** Aminoglycosides, most ATN-causing agents

**Mechanism:** Cumulative cellular damage, lysosomal disruption, mitochondrial dysfunction

**Clinical Action:** Extended-interval dosing, therapeutic drug monitoring, biomarker surveillance

10-14

#### Delayed Onset (10-14 Days)

**Drugs:** Beta-lactams, PPIs, Fluoroquinolones (AIN pattern)

**Mechanism:** Immune sensitization, T-cell mediated hypersensitivity

**Clinical Action:** High index of suspicion, corticosteroids for severe AIN, drug withdrawal

Weeks

#### Very Delayed Onset (Weeks to Months)

**Drugs:** Chronic PPI use, chronic NSAID use, cumulative chemotherapy exposure

**Mechanism:** Chronic inflammation, repeated subclinical injury, progressive scarring

**Clinical Action:** Regular monitoring, deprescribing when appropriate, risk-benefit assessment

### 🎯 Essential Drug Nephrotoxicity Pearls

#### 🧬 Structure-Function

- Aminoglycoside toxicity ∝ positive charge
- Higher charge = greater nephrotoxicity
- Mechanism: enhanced cellular uptake
- Clinical relevance: drug selection matters

#### ⚡ Combination Toxicity

- Vanc + Pip-Tazo: 35-45% AKI risk
- Each additional nephrotoxin: +60% risk
- Synergistic, not just additive
- NNH for combinations: 8-10 patients

#### ⏰ Temporal Patterns

- ATN: 5-10 days (delayed recognition)
- AIN: 10-14 days (immune-mediated)
- Crystals: Hours to days (immediate)
- Early recognition crucial for outcomes

#### 🛡️ Prevention Wins

- AUC-guided vancomycin: -33-45% risk
- Extended-interval aminoglycosides: -30-50%
- Proper hydration prevents crystals
- Risk assessment before prescription

#### 🔬 Mechanisms Matter

- ATN: Direct cellular toxicity
- AIN: T-cell mediated hypersensitivity
- Crystals: Physical obstruction
- Different mechanisms = different treatments

#### 📊 Evidence-Based Care

- Strong RCT evidence for dosing strategies
- Biomarkers improve early detection
- Protocol-driven monitoring reduces AKI
- Electronic alerts help prevention

### 🔍 Explore Specific Drug Classes

📚 For Educational Purposes Only

© 2025 Andrew Bland MD - All Rights Reserved

## 📚 Sources

1.  **Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S.** Triple-whammy AKI risk: diuretics + ACEi/ARB + NSAID. *BMJ.* 2013;346:e8525. [PMID: 23299844](https://pubmed.ncbi.nlm.nih.gov/23299844/).
2.  **Perazella MA, Rosner MH.** Drug-Induced Acute Kidney Injury. *Clin J Am Soc Nephrol.* 2022;17(8):1220-1233. [PMID: 35273009](https://pubmed.ncbi.nlm.nih.gov/35273009/). *— Comprehensive review of drug-induced AKI mechanisms.*
3.  **Moayyedi P, et al; COMPASS Investigators.** Safety of Proton Pump Inhibitors. *Gastroenterology.* 2019;157(3):682-691.e2. [PMID: 31152740](https://pubmed.ncbi.nlm.nih.gov/31152740/).
4.  **Muriithi AK, Nasr SH, Leung N.** Urine eosinophils for AIN. *Clin J Am Soc Nephrol.* 2013;8(11):1857-1862. [PMID: 24052222](https://pubmed.ncbi.nlm.nih.gov/24052222/).


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/aki/drug-induced/index.html) · Markdown synchronized October 3, 2026.